These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12658968)

  • 1. [Information regarding adverse drug effects and treatment indications ("package inserts") exemplified by cervistatin (Lipobay)].
    Braun RN; Halhuber MJ; Hitzenberger G
    Wien Med Wochenschr; 2003; 153(3-4):80-2. PubMed ID: 12658968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baycol withdrawn from market.
    SoRelle R
    Circulation; 2001 Aug; 104(8):E9015-6. PubMed ID: 11521677
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and statin therapy: reconsidering the risks and benefits.
    Gotto AM
    Arch Intern Med; 2003 Mar; 163(6):657-9. PubMed ID: 12639194
    [No Abstract]   [Full Text] [Related]  

  • 4. [Rhabdomyolysis following cerivastatin monotherapy--implications for therapy with HMG-CoA reductase inhibitors].
    Sparing R; Sellhaus B; Noth J; Block F
    Nervenarzt; 2003 Feb; 74(2):167-71. PubMed ID: 12596018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muscular adverse effects of statins.
    Prescrire Int; 2003 Feb; 12(63):21. PubMed ID: 12602397
    [No Abstract]   [Full Text] [Related]  

  • 6. Bayer's response to "potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis".
    Piorkowski JD
    JAMA; 2004 Dec; 292(21):2655-7; discussion 2658-9. PubMed ID: 15572725
    [No Abstract]   [Full Text] [Related]  

  • 7. [Safety profile of statins].
    Prieto JC
    Rev Med Chil; 2001 Nov; 129(11):1237-40. PubMed ID: 11836874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy.
    Pogson GW; Kindred LH; Carper BG
    Am J Cardiol; 1999 Apr; 83(7):1146. PubMed ID: 10190540
    [No Abstract]   [Full Text] [Related]  

  • 9. Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor.
    Stein EA
    Drugs; 1998; 56 Suppl 1():25-31; discussion 33. PubMed ID: 9740538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin.
    Mantel-Teeuwisse AK; Klungel OH; Egberts TC; Verschuren WM; Porsius AJ; de Boer A
    Drug Saf; 2004; 27(1):63-70. PubMed ID: 14720086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin safety.
    Foxton J
    Nurs Stand; 2001 Sep 19-25; 16(1):20. PubMed ID: 11977679
    [No Abstract]   [Full Text] [Related]  

  • 12. HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions.
    Huynh T; Cordato D; Yang F; Choy T; Johnstone K; Bagnall F; Hitchens N; Dunn R
    Intern Med J; 2002; 32(9-10):486-90. PubMed ID: 12380704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerivastatin-induced rhabdomyolysis: 11 case reports.
    Ravnan SL; Locke C; Yee WP; Haase K
    Pharmacotherapy; 2002 Apr; 22(4):533-7. PubMed ID: 11939690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
    Chang JT; Staffa JA; Parks M; Green L
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The withdrawal of Baycol (cerivastatin).
    Griffin JP
    Adverse Drug React Toxicol Rev; 2001 Dec; 20(4):177-80. PubMed ID: 11770168
    [No Abstract]   [Full Text] [Related]  

  • 16. Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction.
    Kind AH; Zakowski LJ; McBride PE
    WMJ; 2002; 101(7):53-6. PubMed ID: 12426921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. By the way, doctor...I read about Baycol, the cholesterol-lowering drug being taken off the market because it caused fatal muscle damage. I don't take it, but I do take another statin. Should I be worried?
    Lee TH
    Harv Health Lett; 2001 Nov; 27(1):8. PubMed ID: 11724700
    [No Abstract]   [Full Text] [Related]  

  • 18. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.
    Psaty BM; Furberg CD; Ray WA; Weiss NS
    JAMA; 2004 Dec; 292(21):2622-31. PubMed ID: 15572720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of German package inserts.
    Fuchs J; Hippius M; Schaefer M
    Int J Clin Pharmacol Ther; 2006 Jan; 44(1):8-13. PubMed ID: 16425965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductase inhibitor, in patients with primary hypercholesterolemia.
    Sasaki J; Arakawa K; Yamamoto K; Kobori S; Ageta M; Kono S
    Clin Ther; 1998; 20(3):539-48. PubMed ID: 9663369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.